|
gptkbp:instanceOf
|
monoclonal antibody
|
|
gptkbp:analyzes
|
filed
|
|
gptkbp:barrelLength
|
high
|
|
gptkbp:clinicalTrials
|
high
Phase 1
pending
multiple sites
NCT02942329
|
|
gptkbp:community_service
|
overall survival
|
|
gptkbp:compatibleWith
|
inhibits tumor growth
|
|
gptkbp:contraindication
|
required
immune-related adverse events
|
|
gptkbp:currentStatus
|
conducted
|
|
gptkbp:dataUsage
|
established
|
|
gptkbp:developedBy
|
gptkb:Xencor
|
|
gptkbp:dosageForm
|
every 2 weeks
|
|
gptkbp:drugInterdiction
|
monitored in trials
enhances T-cell response
|
|
gptkbp:environmentalConcerns
|
ongoing
|
|
gptkbp:formulation
|
liquid
|
|
gptkbp:hasVariants
|
with chemotherapy
|
|
gptkbp:healthcare
|
ongoing
specific cancer types
|
|
gptkbp:historicalResearch
|
combination therapies
with pharmaceutical companies
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
XmAb18050
|
|
gptkbp:impact
|
varies by trial
|
|
gptkbp:is_monitored_by
|
immune response
|
|
gptkbp:isPortrayedBy
|
2015
|
|
gptkbp:mandates
|
solid tumors
|
|
gptkbp:origin
|
humanized
|
|
gptkbp:patentAssignee
|
gptkb:Xencor,_Inc.
|
|
gptkbp:regulatoryCompliance
|
under investigation
|
|
gptkbp:relatedTo
|
immune system
|
|
gptkbp:research
|
grants and investments
|
|
gptkbp:research_areas
|
immuno-oncology
|
|
gptkbp:researchFocus
|
oncology
|
|
gptkbp:researchInterest
|
academic institutions
obtained
related to trials
|
|
gptkbp:route
|
intravenous
|
|
gptkbp:safetyFeatures
|
monitored
|
|
gptkbp:sponsor
|
gptkb:Xencor,_Inc.
|
|
gptkbp:status
|
investigational
|
|
gptkbp:storage
|
refrigerated
|
|
gptkbp:targets
|
PD-1
patients with advanced cancer
|
|
gptkbp:triggerType
|
immune checkpoint inhibition
blocks PD-1 receptor
|
|
gptkbp:usedIn
|
cancer therapy
|